PMID- 28600675 OWN - NLM STAT- MEDLINE DCOM- 20180730 LR - 20181113 IS - 1699-3055 (Electronic) IS - 1699-048X (Linking) VI - 19 IP - 11 DP - 2017 Nov TI - A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. PG - 1350-1357 LID - 10.1007/s12094-017-1675-5 [doi] AB - PURPOSE: Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. METHODS: Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified. RESULTS: The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score >/=7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p < 0.05). CD133 was expressed in 69 (96%) patients. The median CD133+ expression in circulating tumor cells CTCs was higher among the 21 AR-V7 positive cases versus AR-V7 negative (7 vs. 3). Androgen Receptor and PTEN fluorescence in situ hybridization (FISH) on CD133+ captured cells were performed: 37 cases showed >/=four CD133+ CTCs, of which 81% showed an increased AR copy number. This percentage was similar in both AR-V7-positive and AR-V7-negative patients. A total of 68% of the cases showed deletion of PTEN: 70% were ARV-7 positive vs. 67%, which were AR-V7 negative. CONCLUSIONS: Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors. FAU - Garcia, J L AU - Garcia JL AD - Institute of Biomedical Research of Salamanca (IBSAL), Centro de Investigacion del Cancer-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. jlgarcia@usal.es. FAU - Lozano, R AU - Lozano R AD - Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Misiewicz-Krzeminska, I AU - Misiewicz-Krzeminska I AD - Institute of Biomedical Research of Salamanca (IBSAL), Centro de Investigacion del Cancer-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Fernandez-Mateos, J AU - Fernandez-Mateos J AD - Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Krzeminski, P AU - Krzeminski P AD - Institute of Biomedical Research of Salamanca (IBSAL), Centro de Investigacion del Cancer-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Alfonso, S AU - Alfonso S AD - Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Marcos, R A AU - Marcos RA AD - Dpto. de Oncologia Medica, Complejo Asistencial Nuestra Senora de Sonsoles, Av.Juan Carlos I, s/n, 05071, Avila, Spain. FAU - Garcia, R AU - Garcia R AD - Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Gomez-Veiga, F AU - Gomez-Veiga F AD - Urology Department, Hospital Universitario de Salamanca Grupo de Investigacion Traslacional de Urologia (GITUR), Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Virseda, A AU - Virseda A AD - Urology Department, Hospital Universitario de Salamanca Grupo de Investigacion Traslacional de Urologia (GITUR), Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Herrero, M AU - Herrero M AD - Urology Department, Hospital Universitario de Salamanca Grupo de Investigacion Traslacional de Urologia (GITUR), Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. FAU - Olmos, D AU - Olmos D AD - Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernandez Almagro, 3, 28029, Madrid, Spain. AD - Medical Oncology Department, CNIO-IBIMA Genitourinary Cancer Clinical Research Unit, Hospital Universitario Virgen de la Victoria y Regional de Malaga, Campus de Teatinos S/N, 29010, Malaga, Spain. FAU - Cruz-Hernandez, J J AU - Cruz-Hernandez JJ AD - Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. jjcruz@usal.es. LA - eng GR - GRS 992/A/14 y BIO/SA35/14/Partiality supported by Grant from Gerencia Regional de Salud, Junta de Castilla y Leon (Refs : and I/ PT - Journal Article DEP - 20170609 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 RN - 0 (AC133 Antigen) RN - 0 (AR protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Androgen) SB - IM MH - AC133 Antigen/*metabolism MH - *Alternative Splicing MH - Biomarkers, Tumor/*blood/genetics MH - Follow-Up Studies MH - Humans MH - Immunoassay MH - Male MH - Nanomedicine MH - Neoplastic Cells, Circulating/*metabolism/pathology MH - Pilot Projects MH - Prognosis MH - Prostatic Neoplasms/*blood/genetics/pathology MH - Receptors, Androgen/*genetics OTO - NOTNLM OT - AR-V7 OT - Androgen receptor OT - CD133 OT - Capillary nano-immunoassay OT - Circulating tumor cells OT - PTEN EDAT- 2017/06/11 06:00 MHDA- 2018/07/31 06:00 CRDT- 2017/06/11 06:00 PHST- 2017/01/19 00:00 [received] PHST- 2017/05/12 00:00 [accepted] PHST- 2017/06/11 06:00 [pubmed] PHST- 2018/07/31 06:00 [medline] PHST- 2017/06/11 06:00 [entrez] AID - 10.1007/s12094-017-1675-5 [pii] AID - 10.1007/s12094-017-1675-5 [doi] PST - ppublish SO - Clin Transl Oncol. 2017 Nov;19(11):1350-1357. doi: 10.1007/s12094-017-1675-5. Epub 2017 Jun 9.